Today: 19 April 2026
Expedia Group (EXPE) soars on Q3 2025 beat and higher full‑year outlook; B2B bookings power rally — Nov. 7, 2025
7 November 2025
2 mins read

Expedia Group (EXPE) soars on Q3 2025 beat and higher full‑year outlook; B2B bookings power rally — Nov. 7, 2025

Expedia Group, Inc. (NASDAQ: EXPE) reported stronger‑than‑expected third‑quarter results after the bell on Nov. 6 and raised its 2025 guidance. Shares jumped as much as ~16% in pre‑market trading today (Nov. 7) as investors cheered accelerating B2B momentum and margin expansion.

Key takeaways

  • Q3 2025 topped guidance: Revenue $4.41B (+9% y/y); gross bookings $30.73B (+12%); adjusted EBITDA $1.45B (+16%; ~33% margin); adjusted EPS $7.57 (+23%). Room nights 108.2M (+11%).
  • B2B strength: B2B gross bookings rose 26% y/y and B2B revenue grew 18%, continuing a multi‑quarter streak of double‑digit growth. Advertising revenue grew 16%.
  • Guidance raised: For FY 2025, Expedia now sees revenue up 6%–8% and gross bookings up 6%–8%, with ~2 percentage points of adjusted EBITDA margin expansion (prior outlook: ~1 point). For Q4 2025, management guides to ~7% gross bookings growth and 6%–7% revenue growth.
  • Capital returns: Expedia repurchased $451M of stock in Q3 and declared a $0.40 quarterly dividend payable Dec. 11, 2025 (record date Nov. 19, 2025).
  • Market reaction: Shares spiked in early trade on the outlook boost and continued B2B gains, with analysts highlighting the cleaner path to margin expansion.

What happened

Expedia said demand accelerated into the September quarter, with U.S. room‑nights growing at the fastest pace in over three years while international momentum remained solid. CEO Ariane Gorin pointed to reinforcing effects of its two‑sided marketplace and execution against strategic priorities as drivers of the outperformance.

The company’s B2B platform—powering partners like travel agencies, banks and offline sellers—again led the way: B2B bookings +26% y/y and B2B revenue +18%. That mix shift, coupled with expense discipline, lifted adjusted EBITDA margin by ~208 bps to roughly 33% in Q3. Advertising also provided a tailwind, up 16% year over year.


By the numbers (Q3 2025)

  • Gross bookings:$30.73B (+12% y/y)
  • Revenue:$4.41B (+9%)
  • Adjusted EBITDA:$1.45B (+16%); ~32.9% margin
  • Adjusted EPS:$7.57 (+23%)
  • Room nights:108.2M (+11%)
  • Share repurchases:$451M in Q3
  • Dividend:$0.40 per share declared Nov. 6; payable Dec. 11, 2025
    These figures come from Expedia’s earnings materials and investor update.

2025 outlook: raised across the board

Management lifted full‑year guidance to 6%–8% revenue growth and 6%–8% gross bookings growth, and now expects ~2 points of adjusted EBITDA margin expansion for 2025 (previously ~1 point). For the holiday quarter (Q4 2025), Expedia targets ~7% gross bookings growth and 6%–7% revenue growth.

External reporting echoed the stronger setup, with pre‑market gains of about 15%–16% as investors focused on the higher margin outlook and B2B traction. Reuters also highlighted that Asia room‑nights climbed 20%+, while U.S. growth showed share gains amid more price‑sensitive travelers.


Street reaction today (Nov. 7, 2025)

  • Piper Sandler upgraded EXPE to Neutral from Underweight and raised its price target to $250 following the print.
  • RBC Capitallifted its target to $260; other firms raised targets as well, citing accelerating bookings and operating leverage.
  • Coverage also noted that Expedia’s partnerships and AI roadmap help calm disruption fears while preserving marketing efficiency.

Why it matters

  • Mix shift to B2B: B2B continues to outgrow consumer travel, providing steadier, higher‑visibility revenue and cushioning against consumer cyclicality.
  • Margin credibility: The step‑up from ~1 point to ~2 points of expected margin expansion for 2025 suggests Expedia’s re‑platforming and marketing optimization are flowing through to profitability.
  • Travel demand breadth: Management and third‑party reporting indicate travel demand remains resilient across income tiers—not just among premium travelers—supporting volumes into the holiday quarter.

What to watch next

  1. Holiday quarter cadence: Can Expedia hit its Q4 guide (revenue +6%–7%; bookings ~+7%) amid a mixed U.S. macro?
  2. B2B pipeline & partner adds: Sustaining ~20%+ B2B growth will be key to the multi‑year margin story.
  3. Regional mix: With Asia room‑nights up 20%+, watch whether international strength offsets any U.S. softness.
  4. Capital returns: Follow‑through on dividend continuity and buybacks after the Q3 $451M repurchase.

This article is for informational purposes and is not investment advice.

A technology and finance expert writing for TS2.tech. He analyzes developments in satellites, telecommunications, and artificial intelligence, with a focus on their impact on global markets. Author of industry reports and market commentary, often cited in tech and business media. Passionate about innovation and the digital economy.

Stock Market Today

  • 2 TSX Stocks Under $100 with Strong Upside Potential
    April 18, 2026, 9:56 PM EDT. CES Energy (TSX:CEU) and Bird Construction are two TSX-listed stocks priced below $100 that offer significant growth potential. CES Energy provides consumable chemical solutions to oil and gas producers, benefiting from rising service intensity and demand for advanced chemical treatments. Despite softer drilling activity, CES's revenue growth remains robust, supported by its asset-light model and strategic acquisitions. Macro trends like growing global energy demand and LNG infrastructure expansion further boost its outlook. Bird Construction, also trading under $100, stands out for its presence in the construction sector, which benefits from infrastructure spending and urban development. Both companies show disciplined capital allocation and resilient revenue drivers, making them attractive for investors seeking accessible entry points and potential capital appreciation on the TSX.

Latest article

Why Definium Therapeutics’ LSD-Based Drug Has Wall Street Watching 2026

Why Definium Therapeutics’ LSD-Based Drug Has Wall Street Watching 2026

18 April 2026
Definium Therapeutics shares rose to $22.68 after Stifel and Piper Sandler initiated coverage with Buy ratings, citing late-stage trials of DT120, an LSD-based tablet for anxiety and depression. The company will host an investor day April 22 in New York to discuss upcoming Phase 3 data. DT120 is in four pivotal studies, with top-line results expected through 2026. Johnson & Johnson and Compass Pathways are advancing rival clinic-based psychiatric drugs.
Block (XYZ) Stock Sinks ~15% After Q3 Miss—Cash App Hits 58M Users as Square GPV Grows 12% (Nov. 7, 2025)
Previous Story

Block (XYZ) Stock Sinks ~15% After Q3 Miss—Cash App Hits 58M Users as Square GPV Grows 12% (Nov. 7, 2025)

CCC Intelligent Solutions (CCC) News Today: Advent Prices 37.3M‑Share Secondary at $7.79; Ticker Now “CCC” — Nov. 7, 2025
Next Story

CCC Intelligent Solutions (CCC) News Today: Advent Prices 37.3M‑Share Secondary at $7.79; Ticker Now “CCC” — Nov. 7, 2025

Go toTop